Sam Denmeade, M.D.

Samuel Ray Denmeade, M.D.

Headshot of Sam Denmeade
  • Director Genitourinary Oncology Division
  • Professor of Oncology

Languages: English, Spanish


Bladder Cancer, Clinical Trials, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer more

Research Interests

Bipolar Androgen Therapy, Hormonal Resistance, Tumor Metabolism, Immunotherapy, Targeted Drug Development; Bladder Cancer; Prostate and Renal Cancer; Cancer imaging; Targeted therapies for cancer more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps


Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer.

Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine.

His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development.

Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation.  He is the Editor-in-Chief of the medical journal The Prostate. more


  • Director Genitourinary Oncology Division
  • Professor of Oncology
  • Professor of Pharmacology and Molecular Sciences
  • Professor of Urology

Departments / Divisions

Centers & Institutes



  • MD; Columbia University College of Physicians and Surgeons (1989)


  • Internal Medicine; The University of Chicago Medical Center (1992)


  • Oncology; Johns Hopkins University School of Medicine (1997)

Research & Publications

Clinical Trial Keywords

kidney cancer; bladder cancer; prostate cancer

Clinical Trials

Learn more about clinical trials at the Johns Hopkins Kimmel Cancer Center.

Selected Publications

View all on PubMed

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castrate-resistant prostate cancer: Results from a pilot clinical study. Sci Trans Med. 2014: In Press

Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. Oncologist. 2023 Apr 7:oyad055

Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, Skaist A, Yegnasubramanian S, Luo J, Brennen WN, Kachhap SK, Antonarakis ES, De Marzo AM, Isaacs JT, Markowski MC, Denmeade SR. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022 Dec 1;132(23):e162396

Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 Feb 22:JCO2002759

Denmeade SR, Antonarakis EA, Markowski MC. Bipolar Androgen Therapy (BAT): A Patient’s Guide. Prostate, 2022 May;82(7):753-762

Contact for Research Inquiries

The Skip Viragh Outpatient Cancer Building
201 N. Broadway
Baltimore, MD 21287 map
Phone: 410-502-8341
Fax: 410-367-2668

Email me

Academic Affiliations & Courses

Graduate Program Affiliation

Chemical and Biomolecular Engineering

Activities & Honors


  • The Carolyn and Bill Stutt Scholar, Patrick C. Walsh Prostate Cancer Research Fund, 2012
Is this you? Edit Profile
back to top button